← back to search

Félix Gutiérrez

Universitat de Miguel Hernández d'Elx · ES
Area of research
Infectious Diseases · Emergency Medicine
Research interest
Research interests include HIV-related health complications and treatments, HIV/AIDS drug development and treatment, HIV Research and Treatment, and HIV/AIDS Research and Interventions.
h-index
56
citations
16,113
works
445
NIH funding
primary concept
Medicine
email

Recent publications

Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.
2026cited by 0position: contributordoi
Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters.
2025cited by 19position: contributordoi
Influence of patient characteristics and oral lead-in on long-acting cabotegravir and rilpivirine pharmacokinetics and outcomes in people with HIV: a real-world study.
2025cited by 2position: contributordoi
Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy.
2025cited by 1position: contributordoi
Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk.
2025cited by 1position: contributordoi
Early Detection of Cancer and Precancerous Lesions in Persons With HIV Through a Comprehensive Cancer Screening Protocol.
2025cited by 1position: contributordoi
"Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: A French multicentre retrospective study".
2025cited by 0position: contributordoi
Virological Success With Long-Acting Cabotegravir and Rilpivirine Despite Historical Rilpivirine Resistance: A Real-World Case Series.
2025cited by 0position: contributordoi
Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study.
2025cited by 0position: contributordoi
The persistence of low CD4/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function.
2024cited by 4position: contributordoi
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
2023cited by 11position: contributordoi
T-Cell Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Measured by an Interferon-γ Release Assay Is Strongly Associated With Patient Outcomes in Vaccinated Persons Hospitalized With Delta or Omicron Variants.
2023cited by 5position: contributordoi
Improving Recognition of Fracture Risk in People with Human Immunodeficiency Virus: Performance and Model Contribution of Two Common Risk Assessment Tools.
2023cited by 4position: contributordoi
Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV.
2023cited by 4position: contributordoi
Integrating SARS-CoV-2-specific interferon-γ release assay testing in the evaluation of patients hospitalized with COVID-19.
2023cited by 3position: contributordoi
Unplanned pregnancies and social and partner support during pregnancy in Spanish women living with HIV.
2023cited by 3position: contributordoi
Human Immunodeficiency Virus Type 1 RNA Levels in Rectal and Seminal Compartments After Switching to Long-Acting Cabotegravir Plus Rilpivirine: A Longitudinal Study.
2023cited by 2position: contributordoi
Immunologic phenotype of patients with long-COVID syndrome of 1-year duration.
2022cited by 40position: contributordoi
Clinical Performance of a Standardized Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Interferon-γ Release Assay for Simple Detection of T-Cell Responses After Infection or Vaccination.
2022cited by 31position: contributordoi
Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation.
2022cited by 15position: contributordoi
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade.
2022cited by 12position: contributordoi
Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens.
2022cited by 12position: contributordoi
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
2022cited by 11position: contributordoi
Integrase inhibitors in children and adolescents: clinical use and resistance.
2022cited by 7position: contributordoi
Diabetes Does Not Increase the Risk of Hospitalization Due to COVID-19 in Patients Aged 50 Years or Older in Primary Care-APHOSDIAB-COVID-19 Multicenter Study.
2022cited by 3position: contributordoi
Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain.
2022cited by 2position: contributordoi
Pericarditis caused by Mycobacterium africanum: case report.
2022cited by 0position: contributordoi
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
JAMA 2021cited by 718position: middledoi
Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study.
2021cited by 120position: contributordoi
Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study.
2021cited by 48position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Mar Masiá · Hospital Universitario Virgen de la Arrixaca44 papers (2019–2025) · 32 papers (2019–2026) · 19 papers (2019–2025)Marta Fernández-González · University of Oxford19 papers (2019–2025)Javier García-Abellán · 12 papers (2020–2025)Sergio Padilla · Hospital General Universitario de Elche12 papers (2020–2025)David Dalmau · Universitat de Barcelona12 papers (2019–2022)José Alberto García · Hospital General Universitario de Elche10 papers (2020–2025)Inma Jarrin · Universitat de Barcelona10 papers (2019–2023)José Ramón Arribas · Hospital Universitario La Paz8 papers (2019–2022)Santiago Moreno · Universidad del Rosario8 papers (2019–2023)Juan Berenguer · Escuela Nacional de Sanidad8 papers (2019–2020)Christine Katlama · Inserm5 papers (2019–2023)Sergio Serrano‐Villar · Instituto Cajal5 papers (2020–2022)Carmen de Mendoza · Hospital Universitario Puerta de Hierro Majadahonda5 papers (2019–2019)Chloe M. Orkin · Royal London Hospital5 papers (2019–2023)Leandro López · Centro de Investigación Biomédica en Red5 papers (2025–2025)Vanesa Agulló · Hospital General Universitario de Elche5 papers (2020–2023)Christian Ledesma · Universidad Complutense de Madrid5 papers (2025–2025)Vincent Soriano · Centre for Plant Biotechnology and Genomics5 papers (2019–2019)